Goldman Sachs Group Inc. Reduces Holdings in Fulcrum Therapeutics, Inc. $FULC

Goldman Sachs Group Inc. lowered its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) by 25.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 402,600 shares of the company’s stock after selling 139,658 shares during the quarter. Goldman Sachs Group Inc. owned about 0.75% of Fulcrum Therapeutics worth $1,159,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Algert Global LLC increased its position in shares of Fulcrum Therapeutics by 6.0% during the 1st quarter. Algert Global LLC now owns 36,147 shares of the company’s stock valued at $104,000 after purchasing an additional 2,030 shares during the last quarter. American Century Companies Inc. grew its holdings in shares of Fulcrum Therapeutics by 2.6% in the first quarter. American Century Companies Inc. now owns 123,711 shares of the company’s stock valued at $356,000 after purchasing an additional 3,100 shares in the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Fulcrum Therapeutics in the 4th quarter worth approximately $38,000. Brooklyn Investment Group boosted its position in shares of Fulcrum Therapeutics by 209.7% during the first quarter. Brooklyn Investment Group now owns 12,190 shares of the company’s stock valued at $35,000 after buying an additional 8,254 shares during the period. Finally, Jump Financial LLC purchased a new stake in Fulcrum Therapeutics in the first quarter worth $30,000. Institutional investors own 89.83% of the company’s stock.

Fulcrum Therapeutics Stock Performance

Shares of NASDAQ FULC opened at $7.39 on Monday. The firm has a market capitalization of $399.73 million, a P/E ratio of -6.06 and a beta of 2.82. Fulcrum Therapeutics, Inc. has a one year low of $2.32 and a one year high of $8.50. The company’s fifty day moving average is $7.04 and its two-hundred day moving average is $5.76.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings results on Tuesday, July 29th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.01. On average, sell-side analysts forecast that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

FULC has been the subject of a number of research reports. Wall Street Zen lowered shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 9th. Royal Bank Of Canada boosted their price objective on Fulcrum Therapeutics from $4.00 to $5.00 and gave the company a “sector perform” rating in a report on Wednesday, July 30th. HC Wainwright upgraded Fulcrum Therapeutics from a “neutral” rating to a “buy” rating and lifted their price target for the company from $4.00 to $12.00 in a research note on Tuesday, July 29th. Finally, Piper Sandler restated an “overweight” rating and issued a $9.00 target price (up previously from $6.00) on shares of Fulcrum Therapeutics in a research report on Thursday, May 29th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, Fulcrum Therapeutics has a consensus rating of “Buy” and an average target price of $9.60.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.